PT-141 (Bremelanotide) Dosage: Vyleesi Label vs Off-Label Use
PT-141 is the peptide bremelanotide, approved by the FDA as Vyleesi for premenopausal hypoactive sexual desire disorder (HSDD) at a specific labelled dose. The FDA label sets a maximum frequency and contraindicates certain populations. Off-label use at different doses or in other populations is not regulator-validated.
PT-141 (bremelanotide) is FDA-approved as Vyleesi for premenopausal HSDD with a specific labelled dose and frequency. The FDA label restricts use to the approved indication and contraindicates uncontrolled hypertension and known cardiovascular disease. Off-label dosing is not regulator-validated. Speak to your prescriber.
Key Takeaways
- Bremelanotide is FDA-approved as Vyleesi for premenopausal HSDD with a specific labelled dose and maximum frequency.
- Per the FDA label, Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease, because of transient blood-pressure increases.
- Common labelled adverse reactions include nausea, flushing, injection-site reactions, headache, and vomiting.
- Off-label use at different doses or in other populations is not regulator-validated.
- Allmeds does not publish off-label dosing protocols.
Approved Vyleesi dosing
The FDA-approved indication is premenopausal HSDD. The Vyleesi label specifies a dose administered as needed, a maximum frequency, and dosing instructions that include subcutaneous injection in the abdomen or thigh. The specific dose and frequency are part of the prescribing information your clinician will discuss; Allmeds does not republish self-administration protocols here. Speak to your prescriber.
Label warnings and contraindications
The Vyleesi FDA label includes:
- Contraindicated in uncontrolled hypertension and known cardiovascular disease, because of transient increases in blood pressure and decreases in heart rate after each dose.
- Common adverse reactions: nausea, flushing, injection-site reactions, headache, vomiting.
- Risk of focal hyperpigmentation, particularly with frequent use.
- Drug interactions: Vyleesi can affect absorption of co-administered oral drugs with narrow therapeutic indices.
Off-label dosing
PT-141 marketed off-label (for non-HSDD uses, in men, or at different doses) is not regulator-validated. Compounded versions sold outside the approved Vyleesi product are not pharmaceutical-grade in the same sense.
Check your medications before any change
Allmeds scans interactions across your full list. Free for individuals; team plans available.
Common Questions
The FDA label specifies the dose and frequency. Allmeds does not republish self-administration protocols. Discuss with your prescriber, who will share the prescribing information.
Vyleesi is FDA-approved for premenopausal HSDD in women. PT-141 use in men is off-label and not regulator-validated.
No. Compounded PT-141 is not equivalent to the FDA-approved Vyleesi product. Purity, potency, sterility, and label-defined safety are not guaranteed in compounded versions.
Per the FDA label, Vyleesi is contraindicated in uncontrolled hypertension and known cardiovascular disease, because of transient blood-pressure increases. Pre-existing hypertension is a discussion to have with your prescriber.